| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Total assets | 109,700 | |||
| Accounts payable and accrued expenses, including 466 and 19 to related parties as of june 30, 2025 and december 31, 2024, respectively | 7,572 | |||
| Lease liability, short term | 15 | |||
| Dividends payable | 115 | |||
| Derivative liability | 105,498 | |||
| Total current liabilities | 113,200 | |||
| Total liabilities | 113,200 | |||
| Accumulated deficit | -278,529 | |||
| Common stock, 0.001 par value, authorized 200,000,000 shares, 30,793,135 and 17,239,096 issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 31 | |||
| Additional paid-in-capital | 273,343 | |||
| Accumulated other comprehensive income | 1,538 | |||
| Total stockholders deficit attributable to biosig technologies, inc | -3,617 | |||
| Non-controlling interest | 33 | |||
| Total stockholders deficit | -3,584 | |||
| Redeemable series c 9 convertible preferred stock, 0.001 par value, 1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding (liquidation preference of 105 cumulative dividends payable of 115 and 110 as of june 30, 2025 and december 31, 2024, respectively) | 105 | |||
| Total liabilities, mezzanine equity and stockholders deficit | 109,721 | |||
BioSig Technologies, Inc. (BSGM)
BioSig Technologies, Inc. (BSGM)